AAVantgarde to Participate in ARVO 2026, with Presentations at Key Pre-events and New Clinical Data from the LUCE Phase 1/2 Study
MILAN, 23 April, 2026 — AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering next-generation gene…